94-1083. Talc; Consumer Uses and Health Perspectives; Public Meetings  

  • [Federal Register Volume 59, Number 10 (Friday, January 14, 1994)]
    [Unknown Section]
    [Page 0]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 94-1083]
    
    
    [[Page Unknown]]
    
    [Federal Register: January 14, 1994]
    
    
    =======================================================================
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    
    21 CFR Part 347
    
    [Docket No. 78N-0021]
    
     
    
    Talc; Consumer Uses and Health Perspectives; Public Meetings
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Notice of public meetings.
    
    -----------------------------------------------------------------------
    
    SUMMARY: The Food and Drug Administration (FDA) and the International 
    Society of Regulatory Toxicology and Pharmacology (ISRTP) are 
    announcing forthcoming public meetings to discuss the latest 
    toxicologic and epidemiologic studies and how they reflect on issues 
    related to the safe use of talc in consumer products.
    
    DATES: The meetings will be held on Monday, January 31, 1994, and 
    Tuesday, February 1, 1994, 9 a.m. to 4:30 p.m. Registration by January 
    15, 1994, is required. Interested persons, whether or not they are able 
    to attend, may submit written comments on the skin protectant drug 
    product aspects of the issues described in this notice by March 2, 
    1994, referencing the docket number found in the heading of this 
    document. Three copies of all comments are to be submitted, except that 
    individuals may submit one copy.
    
    ADDRESSES: The meetings will be held at the Lister Hill Auditorium, 
    National Institutes of Health, Bethesda, MD. Submit written comments to 
    the Dockets Management Branch (HFA-305), Food and Drug Administration, 
    rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857.
    
    FOR FURTHER INFORMATION CONTACT:
        Regarding registration and over-the-counter (OTC) skin protectant 
    drug products contact: William E. Gilbertson, Center for Drug 
    Evaluation and Research (HFD-810), Food and Drug Administration, 5600 
    Fishers Lane, Rockville, MD 20857, 301-594-5000.
        Regarding cosmetic products contact: John E. Bailey, Jr., Center 
    for Food Safety and Applied Nutrition (HFS-100), Food and Drug 
    Administration, 200 C St. SW., Washington, DC 20204, 202-205-4530.
    
    SUPPLEMENTARY INFORMATION: In the Federal Register of June 20, 1990 (55 
    FR 25204 at 25232), FDA proposed talc, 45 to 100 percent, as Category I 
    (generally recognized as safe and effective and not misbranded) as an 
    OTC skin protectant active ingredient for the treatment and prevention 
    of diaper rash. Specific warnings and directions were proposed for 
    powder products containing talc. The final monograph for OTC skin 
    protectant drug products will be published in a future issue of the 
    Federal Register. The discussion of talc at these public meetings may 
    be considered by the agency in the preparation of this final monograph 
    for OTC skin protectant drug products.
        The purpose of these meetings is to provide a forum for an updated 
    discussion of the origins, manufacture, characterization, toxicology, 
    and epidemiology of talc and related products. The principal focus will 
    be on the latest toxicologic and epidemiologic studies, particularly as 
    they reflect on the safe uses of talc in consumer products.
        The following topic areas will be discussed: (1) Characteristics of 
    cosmetic-grade talc; (2) a history of the uses of talc in a variety of 
    consumer products; (3) current quality control measures to insure 
    safety; (4) the regulatory history of talc; (5) recent National 
    Toxicology Program studies of chronic pulmonary exposure of rodents to 
    talc and the relevance of these studies to human risk assessment; and 
    (6) the significance of contrasting epidemiologic studies of talc 
    exposure. Speakers and panelists will include well-known regulatory 
    specialists, toxicologists, epidemiologists, pathologists, talc product 
    manufacturers, talc production experts, and consumer representatives. A 
    critical panel discussion by speakers and invited experts will complete 
    each session.
    
        Dated: January 11, 1994
    Michael R. Taylor,
    Deputy Commissioner for Policy.
    [FR Doc. 94-1083 Filed 1-12-94; 8:47 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Published:
01/14/1994
Department:
Food and Drug Administration
Entry Type:
Uncategorized Document
Action:
Notice of public meetings.
Document Number:
94-1083
Dates:
The meetings will be held on Monday, January 31, 1994, and Tuesday, February 1, 1994, 9 a.m. to 4:30 p.m. Registration by January 15, 1994, is required. Interested persons, whether or not they are able to attend, may submit written comments on the skin protectant drug product aspects of the issues described in this notice by March 2, 1994, referencing the docket number found in the heading of this document. Three copies of all comments are to be submitted, except that individuals may submit one ...
Pages:
0-0 (1 pages)
Docket Numbers:
Federal Register: January 14, 1994, Docket No. 78N-0021
Supporting Documents:
» Tab J.10: Memorandum of Telephone Conversation Re: Skin Protectant Drug Products for Over the Counter Human Use; Final Monograph
» Tab I.9: Memorandum of Telephone Conversation Re: Skin Protectant Drug Products for Over the Counter Human Use; Final Monograph
» Tab H.8: Memorandum of Telephone Conversation Re: Skin Protectant Drug Products for Over the Counter Human Use; Final Monograph
» Tab G.7: Memorandum of Meeting Re: Skin Protectant Drug Products for Over the Counter Human Use; Final Monograph
» Tab F.6: Memorandum of Meeting Re: Skin Protectant Drug Products for Over the Counter Human Use; Final Monograph
» Tab E.5: Memorandum of Telephone Conversation Re: Skin Protectant Drug Products for Over the Counter Human Use; Final Monograph
» Tab D.4: Memorandum of Meeting Re: Skin Protectant Drug Products for Over the Counter Human Use; Final Monograph
» Tab C.3: Memorandum of Meeting Re: Skin Protectant Drug Products for Over the Counter Human Use; Final Monograph
» Tab B.2: Memorandum of Telephone Conversation Re: Skin Protectant Drug Products for Over the Counter Human Use; Final Monograph
» Tab A.1: Memorandum of Meeting Re: Skin Protectant Drug Products for Over the Counter Human Use; Final Monograph
CFR: (1)
21 CFR 347